Comparative Pharmacology
Head-to-head clinical analysis: CLOTRIMAZOLE versus KETOZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTRIMAZOLE versus KETOZOLE.
CLOTRIMAZOLE vs KETOZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol biosynthesis and increasing membrane permeability.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
Topical: Apply thin layer to affected area twice daily for 2-4 weeks. Oral troche: 10 mg troche dissolved slowly in mouth 5 times daily for 14 days. Vaginal: One 100 mg suppository intravaginally at bedtime for 7 days, or 200 mg suppository for 3 days, or 500 mg single dose.
200 mg orally once daily with food.
None Documented
None Documented
Clinical Note
moderateClotrimazole + Tranilast
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast."
Clinical Note
moderateClotrimazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tolfenamic acid."
Clinical Note
moderateClotrimazole + Nimesulide
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide."
Clinical Note
moderateTerminal half-life is approximately 3-6 hours; due to rapid hepatic metabolism and extensive tissue distribution, clinical effects persist longer than plasma levels suggest.
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Primarily fecal (biliary) as unchanged drug and metabolites; minimal renal excretion (<1% unchanged).
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Category A/B
Category C
Antifungal
Antifungal
Clotrimazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronic acid."